ConductScience.org, home

Comparison · NCT02787057-ece0fa12

Study Group vs Control Group: Primary Treatment Failure Rate

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Study Group vs Control Group: Primary Treatment Failure Rate. Trial comparisons, record NCT02787057-ece0fa12. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02787057-ece0fa12

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.3250.2010.48wilson
Risk in group 20.20.1050.348wilson
Risk difference, group 1 minus group 20.125-0.06790.307newcombe hybrid score
Risk ratio, group 1 over group 21.630.7573.49log
Odds ratio, group 1 over group 21.930.6955.33log
Number needed to treat, for one more participant with the outcome on Study Group than on Control Group8from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: control.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Study Group
IP vancomycin 1g every 5 days combined with oral moxifloxacin 400mg QD. The duration of treatment was based on ISPD guideline recommendations.~vancomycin: IP vancomycin 1g every 5 days~moxifloxacin: oral moxifloxacin 400mg QD
1340OG001
Group 2Control Group
IP vancomycin 1g every 5 days combined with IP ceftazidime 1g QD. The duration of treatment was based on internatinal society of peritoneal dialysis (ISPD) guideline recommendations.~vancomycin: IP vancomycin 1g every 5 days~ceftazidime: IP ceftazidime 1g QD
840OG000

Outcome

Type
SECONDARY
Title
Primary Treatment Failure Rate
Description
Primary treatment failure was defined as the presence of fever, abdominal pain, and turbid peritoneal dialysate, and if the total peritoneal WBC counts is \>50% of the pretreatment values after 3 days of treatment by the assigned antibiotics
Time frame
after 3 days of treatment by the assigned antibiotics
Population

Source ClinicalTrials.gov

Trial

Title
Vancomycin Plus Moxifloxacin Versus Vancomycin Plus Ceftazidime for the Treatment of Peritoneal Dialysis (PD)-Related Peritonitis
NCT number
NCT02787057
Phases
NA
Conditions
Peritoneal Dialysis Associated Peritonitis
Interventions
vancomycin, moxifloxacin, ceftazidime
Lead sponsor
Peking University First Hospital
Results first posted
2020-03-26

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT02787057-ece0fa12